MedTrace Logo

A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

NCT03711279 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2024-02-29

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to evaluate the efficacy of SHR-1210 plus Apatinib versus AMD plus IFO in participants with soft tissue sarcoma.

Conditions

  • Sarcoma

Interventions

DRUG

SHR-1210 plus Apatinib

SHR-1210 200 mg q3w+ Apatinib 500 mg qd

DRUG

ADM plus IFO or IFO alone

ADM 60 mg/m2 D1 + IFO 2 g/m2 D1-D4 q3w；if the cumulative doses of ADM were beyond 450 mg/m2, the monotherapy of IFO (2 g/m2 D1-D5 q3w) would be used.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yang Yao, M.D. · Shanghai Jiao Tong University Affiliated Sixth People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-22
Primary Completion
2021-06-21
Completion
2021-06-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03711279 on ClinicalTrials.gov